image
Healthcare - Biotechnology - NASDAQ - US
$ 0.2946
-2.13 %
$ 11.1 M
Market Cap
-0.27
P/E
1. INTRINSIC VALUE

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.[ Read More ]

The intrinsic value of one HCWB stock under the base case scenario is HIDDEN Compared to the current market price of 0.295 USD, HCW Biologics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HCWB

image
FINANCIALS
2.84 M REVENUE
-57.72%
-25.7 M OPERATING INCOME
-70.55%
-25 M NET INCOME
-67.74%
-22.5 M OPERATING CASH FLOW
-116.77%
3.8 M INVESTING CASH FLOW
-74.18%
-14.5 K FINANCING CASH FLOW
-0.23%
426 K REVENUE
-31.09%
-3.69 M OPERATING INCOME
75.62%
-3.9 M NET INCOME
74.46%
-2.93 M OPERATING CASH FLOW
39.81%
-37.1 K INVESTING CASH FLOW
-199.62%
2.8 M FINANCING CASH FLOW
45.79%
Balance Sheet Decomposition HCW Biologics Inc.
image
Current Assets 6.4 M
Cash & Short-Term Investments 3.6 M
Receivables 1.54 M
Other Current Assets 1.27 M
Non-Current Assets 22.1 M
Long-Term Investments 1.6 M
PP&E 20.5 M
Other Non-Current Assets 56.5 K
Current Liabilities 8.75 M
Accounts Payable 6.17 M
Short-Term Debt 28.5 K
Other Current Liabilities 2.55 M
Non-Current Liabilities 6.3 M
Long-Term Debt 6.3 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall HCW Biologics Inc.
image
Revenue 2.84 M
Cost Of Revenue 3.42 M
Gross Profit -575 K
Operating Expenses 21 M
Operating Income -25.7 M
Other Expenses -723 K
Net Income -25 M
RATIOS
-20.23% GROSS MARGIN
-20.23%
-904.96% OPERATING MARGIN
-904.96%
-879.52% NET MARGIN
-879.52%
-185.67% ROE
-185.67%
-87.66% ROA
-87.66%
-130.11% ROIC
-130.11%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis HCW Biologics Inc.
image
Net Income -25 M
Depreciation & Amortization 1.14 M
Capital Expenditures -6.2 M
Stock-Based Compensation 1 M
Change in Working Capital -4.64 M
Others -160 K
Free Cash Flow -28.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets HCW Biologics Inc.
image
HCWB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership HCW Biologics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 14, 2023
Bought 3.74 K USD
Wong Hing C
Chief Executive Officer
+ 1800
2.0782 USD
1 year ago
Sep 14, 2023
Bought 1.8 K USD
Winer Gary M
Director
+ 879
2.05 USD
1 year ago
Sep 14, 2023
Bought 337 USD
Winer Gary M
Director
+ 162
2.08 USD
1 year ago
Sep 13, 2023
Bought 92 USD
Winer Gary M
Director
+ 46
2 USD
1 year ago
Sep 13, 2023
Bought 1.02 K USD
Winer Gary M
Director
+ 500
2.05 USD
1 year ago
Sep 13, 2023
Bought 10.5 K USD
Byam Rebecca
Chief Financial Officer
+ 5000
2.098 USD
1 year ago
Sep 12, 2023
Bought 10.4 K USD
Byam Rebecca
Chief Financial Officer
+ 5000
2.0884 USD
1 year ago
Sep 11, 2023
Bought 10.3 K USD
Byam Rebecca
Chief Financial Officer
+ 5000
2.0546 USD
1 year ago
Sep 12, 2023
Bought 1.02 K USD
Winer Gary M
Director
+ 500
2.0499 USD
1 year ago
Sep 11, 2023
Bought 203 USD
Winer Gary M
Director
+ 99
2.05 USD
1 year ago
Sep 08, 2023
Bought 1.9 USD
Winer Gary M
Director
+ 1
1.9 USD
1 year ago
Sep 08, 2023
Bought 10.1 K USD
Byam Rebecca
Chief Financial Officer
+ 5000
2.0222 USD
1 year ago
Sep 07, 2023
Bought 9.74 K USD
Byam Rebecca
Chief Financial Officer
+ 5000
1.9484 USD
1 year ago
Sep 07, 2023
Bought 123 USD
Winer Gary M
Director
+ 63
1.95 USD
1 year ago
Sep 05, 2023
Bought 700 USD
Winer Gary M
Director
+ 400
1.75 USD
1 year ago
Sep 06, 2023
Bought 9.75 K USD
Byam Rebecca
Chief Financial Officer
+ 5000
1.9498 USD
1 year ago
Jun 08, 2023
Bought 21.6 K USD
Flowers Lee
SVP of Business Development
+ 10000
2.1574 USD
1 year ago
Jun 09, 2023
Bought 41.3 K USD
Byam Rebecca
Chief Financial Officer
+ 20000
2.0643 USD
1 year ago
Jun 08, 2023
Bought 10.4 K USD
Byam Rebecca
Chief Financial Officer
+ 4696
2.212 USD
1 year ago
Jun 07, 2023
Bought 40.6 K USD
Byam Rebecca
Chief Financial Officer
+ 20000
2.0316 USD
1 year ago
Jun 06, 2023
Bought 34.8 K USD
Byam Rebecca
Chief Financial Officer
+ 19062
1.8245 USD
1 year ago
Jun 05, 2023
Bought 33.3 K USD
Byam Rebecca
Chief Financial Officer
+ 20000
1.6672 USD
1 year ago
Jun 02, 2023
Bought 1.23 K USD
Wong Hing C
Chief Executive Officer
+ 800
1.5353 USD
1 year ago
Jun 01, 2023
Bought 1.29 K USD
Wong Hing C
Chief Executive Officer
+ 800
1.6178 USD
1 year ago
May 31, 2023
Bought 3.09 K USD
Wong Hing C
Chief Executive Officer
+ 2000
1.546 USD
1 year ago
May 30, 2023
Bought 4.66 K USD
Wong Hing C
Chief Executive Officer
+ 3000
1.5527 USD
1 year ago
May 31, 2023
Bought 750 USD
Winer Gary M
Director
+ 500
1.5 USD
1 year ago
May 30, 2023
Bought 1.29 K USD
Winer Gary M
Director
+ 850
1.5206 USD
1 year ago
May 26, 2023
Bought 33.2 K USD
Byam Rebecca
Chief Financial Officer
+ 20000
1.6598 USD
1 year ago
May 25, 2023
Bought 32.3 K USD
Byam Rebecca
Chief Financial Officer
+ 20000
1.6174 USD
1 year ago
May 24, 2023
Bought 32.2 K USD
Byam Rebecca
Chief Financial Officer
+ 20000
1.6075 USD
1 year ago
May 23, 2023
Bought 7.89 K USD
Byam Rebecca
Chief Financial Officer
+ 5036
1.5662 USD
1 year ago
May 22, 2023
Bought 51 K USD
Byam Rebecca
Chief Financial Officer
+ 33450
1.526 USD
2 years ago
Sep 08, 2022
Bought 16.2 K USD
Wong Hing C
Chief Executive Officer
+ 6000
2.7 USD
2 years ago
Sep 02, 2022
Bought 15.5 K USD
Wong Hing C
Chief Executive Officer
+ 6000
2.58 USD
2 years ago
Aug 30, 2022
Bought 25.6 K USD
Byam Rebecca
Chief Financial Officer
+ 10000
2.5572 USD
2 years ago
Aug 26, 2022
Bought 25.4 K USD
Byam Rebecca
Chief Financial Officer
+ 10000
2.5358 USD
2 years ago
Aug 24, 2022
Bought 125 K USD
Byam Rebecca
Chief Financial Officer
+ 50000
2.5045 USD
2 years ago
Jun 13, 2022
Bought 145 K USD
Byam Rebecca
Chief Financial Officer
+ 58856
2.4634 USD
2 years ago
Jun 10, 2022
Bought 3.33 K USD
Wong Hing C
Chief Executive Officer
+ 1520
2.188 USD
2 years ago
Jun 08, 2022
Bought 3.2 K USD
Winer Gary M
director:
+ 1500
2.1333 USD
2 years ago
Jun 09, 2022
Bought 2.2 K USD
Winer Gary M
Director
+ 1000
2.2 USD
2 years ago
Jun 08, 2022
Bought 2.27 K USD
Winer Gary M
Director
+ 1000
2.2727 USD
2 years ago
Jun 07, 2022
Bought 4.49 K USD
Wong Hing C
Chief Executive Officer
+ 2000
2.245 USD
2 years ago
Jun 06, 2022
Bought 2.1 K USD
Winer Gary M
director:
+ 1000
2.1 USD
2 years ago
Jun 06, 2022
Bought 2.13 K USD
Winer Gary M
Director
+ 1000
2.1273 USD
2 years ago
Jun 02, 2022
Bought 10 K USD
Greene Rick S.
director:
+ 4800
2.0918 USD
2 years ago
Dec 06, 2021
Bought 24.2 K USD
Jiao Jin-an
VP of Development
+ 10000
2.415 USD
3 years ago
Aug 31, 2021
Bought 23 K USD
Wong Hing C
Chief Executive Officer
+ 5830
3.94 USD
3 years ago
Aug 27, 2021
Bought 30.1 K USD
Wong Hing C
Chief Executive Officer
+ 8000
3.7625 USD
3 years ago
Aug 19, 2021
Bought 44 K USD
Byam Rebecca
Chief Financial Officer
+ 10000
4.3979 USD
3 years ago
Aug 31, 2021
Bought 15.1 K USD
Wong Hing C
Chief Executive Officer
+ 3830
3.9348 USD
3 years ago
Aug 30, 2021
Bought 23.6 K USD
Wong Hing C
Chief Executive Officer
+ 6000
3.9333 USD
3 years ago
Aug 27, 2021
Bought 22.6 K USD
Wong Hing C
Chief Executive Officer
+ 6000
3.77 USD
3 years ago
Aug 26, 2021
Bought 25 K USD
Wong Hing C
Chief Executive Officer
+ 6500
3.8415 USD
3 years ago
Aug 25, 2021
Bought 14.8 K USD
Greene Rick S.
Director
+ 3611
4.1045 USD
3 years ago
Aug 23, 2021
Bought 22.2 K USD
Flowers Lee
SVP of Business Development
+ 5605
3.953 USD
3 years ago
Aug 20, 2021
Bought 32.1 K USD
Flowers Lee
SVP of Business Development
+ 7853
4.0837 USD
3 years ago
Aug 19, 2021
Bought 45.2 K USD
Flowers Lee
SVP of Business Development
+ 10532
4.2934 USD
3 years ago
Aug 19, 2021
Bought 44.8 K USD
Flowers Lee
SVP of Business Development
+ 10532
4.2523 USD
3 years ago
Aug 19, 2021
Bought 44 K USD
Byam Rebecca
Chief Financial Officer
+ 10000
4.3979 USD
3 years ago
Jul 22, 2021
Bought 1 M USD
GARRETT SCOTT T
Director
+ 125000
8 USD
3 years ago
Jul 22, 2021
Bought 100 K USD
Rhode Peter
See Remarks
+ 12500
8 USD
3 years ago
Jul 22, 2021
Bought 250 K USD
Flowers Lee
SVP of Business Development
+ 31250
8 USD
3 years ago
Jul 22, 2021
Bought 200 K USD
Byam Rebecca
Chief Financial Officer
+ 25000
8 USD
3 years ago
Jul 22, 2021
Bought 5.02 M USD
Wong Hing C
Chief Executive Officer
+ 627500
8 USD
7. News
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024. globenewswire.com - 2 days ago
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla. globenewswire.com - 2 months ago
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024. globenewswire.com - 3 months ago
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024. globenewswire.com - 6 months ago
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. globenewswire.com - 7 months ago
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023. globenewswire.com - 1 year ago
Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc.  (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy. globenewswire.com - 1 year ago
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota. globenewswire.com - 1 year ago
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023 Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months globenewswire.com - 1 year ago
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023. globenewswire.com - 1 year ago
HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. benzinga.com - 2 years ago
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” globenewswire.com - 2 years ago
8. Profile Summary

HCW Biologics Inc. HCWB

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 11.1 M
Dividend Yield 0.00%
Description HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Contact 2929 North Commerce Parkway, Miramar, FL, 33025 https://www.hcwbiologics.com
IPO Date July 20, 2021
Employees 45
Officers Ms. Rebecca Byam CPA, M.B.A. Chief Financial Officer Dr. Hing C. Wong Ph.D. Founder, Chief Executive Officer, Director & Secretary Mr. Lee D. Flowers Senior Vice President of Business Development Dr. Peter Rhode Ph.D. Chief Scientific Officer & Vice President of Clinical Operations Ms. Nicole Valdivieso Esq. Vice President of Legal Affairs